Overview
Epinephrine, also known as adrenaline, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades , , . On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths . Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity (anaphylactic or anaphylactoid) reactions to drugs, animal serums and other allergens, and to prolong the action of infiltration anesthetics . In addition to the above functions, epinephrine is the primary drug administered during cardiopulmonary resuscitation (CPR) to reverse cardiac arrest , . It can be used in severe cases of croup .
Indication
Epinephrine injection is indicated in the emergency treatment of type I allergic reactions, including anaphylaxis. It is also used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Epinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock . Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics . In addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath . It is also used for the maintenance of mydriasis during intraocular surgery .
Associated Conditions
- Anaphylaxis
- Angioneurotic Edema
- Bleeding
- Bronchospasm
- Complete Heart Block
- Hypotension
- Idiopathic Anaphylaxis
- Laryngotracheobronchitis
- Mild Intermittent Asthma
- Nasal Congestion
- Open Angle Glaucoma (OAG)
- Respiratory Distress
- Severe Asthma
- Syncope
- Type I Hypersensitivity
- Urticaria
- Uterine Contractions
- Ventricular Fibrillation
- Resuscitation in cardiac arrest following anesthetic accidents
- Severe hypersensitivity reactions
- Unresponsive Asystole
- Unresponsive Bradycardia
Research Report
Epinephrine (DB00668): A Comprehensive Monograph on its History, Pharmacology, and Clinical Utility
Introduction
Epinephrine, known also by its British Approved Name, Adrenaline, stands as a paramount molecule in both human physiology and clinical medicine. It is an endogenous catecholamine that functions dually as a hormone, synthesized and released by the chromaffin cells of the adrenal medulla, and as a neurotransmitter within select pathways of the central nervous system.[1] This dual role places it at the center of the body's acute stress response, orchestrating the profound physiological shifts colloquially known as the "fight-or-flight" response.[2] The discovery and isolation of this potent substance over a century ago marked a watershed moment in science, effectively launching the field of endocrinology and providing medicine with one of its most powerful and versatile tools.
The therapeutic utility of epinephrine is a direct translation of its physiological functions. It is the cornerstone of emergency treatment for life-threatening conditions, most notably Type I hypersensitivity reactions, including anaphylaxis, where its multifaceted actions are uniquely suited to counteract systemic collapse.[4] Its potent cardiovascular effects are harnessed in the management of cardiac arrest and as a vasopressor agent to combat profound hypotension in septic shock.[2] Furthermore, its applications extend to the emergency management of severe asthma, as an essential adjunct to local anesthetics, and in ophthalmic procedures to control intraocular pressure and induce mydriasis.[4]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/07/24 | Not Applicable | Not yet recruiting | IVO JURISIC | ||
2025/06/26 | Phase 1 | Not yet recruiting | Dr. George Luciuk | ||
2025/02/26 | Phase 3 | Recruiting | |||
2025/02/19 | Phase 4 | Not yet recruiting | |||
2025/01/23 | Phase 3 | Not yet recruiting | |||
2024/07/30 | Phase 2 | Completed | |||
2024/07/22 | Not Applicable | Not yet recruiting | |||
2024/07/12 | Early Phase 1 | Completed | United States Naval Medical Center, San Diego | ||
2024/06/27 | Phase 2 | Not yet recruiting | NATALIA LOPERA MUNERA | ||
2024/06/13 | Phase 2 | Recruiting | Amin Javer |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Dispensing Solutions, Inc. | 55045-3207 | INTRAMUSCULAR | 0.3 mg in 0.3 mL | 1/31/2012 | |
| Baxter Healthcare Corporation | 0338-0024 | INTRAVENOUS | 64 ug in 1 mL | 2/28/2025 | |
| Medical Purchasing Solutions, LLC | 71872-7117 | INTRAVENOUS | 1 mg in 1 mL | 10/13/2022 | |
| Henry Schein Inc. | 0404-6512 | SUBMUCOSAL | 0.01 mg in 1 mL | 2/8/2024 | |
| REMEDYREPACK INC. | 70518-2781 | INTRAVENOUS, INTRACARDIAC | 0.1 mg in 1 mL | 3/6/2024 | |
| Dentsply Pharmaceutical | 66312-176 | SUBMUCOSAL | 10 ug in 1 mL | 2/5/2024 | |
| Benco Dental | 66975-415 | SUBMUCOSAL | 0.02 mg in 1 mL | 2/5/2024 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1222 | SUBCUTANEOUS | 0.15 mg in 0.15 mL | 12/9/2022 | |
| Henry Schein, Inc. | 0404-9891 | INFILTRATION | 10 ug in 1 mL | 1/12/2022 | |
| Fresenius Kabi USA, LLC | 63323-482 | INFILTRATION, PERINEURAL | 0.01 mg in 1 mL | 8/28/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 8/22/2024 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML | SIN16897P | INJECTION, SOLUTION | 0.1 mg/ml | 11/7/2023 | |
| XYLOCAINE 2% WITH ADRENALINE 1:80,000 INJECTION | SIN05752P | INJECTION | 0.0125 mg/ml | 4/8/1991 | |
| XYLESTESIN-A INJECTION | 3M Deutschland GmbH | SIN06177P | INJECTION | 0.0125 mg/ml | 5/8/1991 |
| Posicaine-100 Injection | Novocol Pharmaceutical of Canada Inc. | SIN14537P | INJECTION, SOLUTION | 0.01mg/ml | 4/10/2014 |
| EpiPen Junior (Epinephrine) Auto-Injector 0.15mg/dose (0.5mg/ml) | SIN13290P | INJECTION | 0.5 mg/ml | 6/7/2007 | |
| UBISTESIN INJECTION | 3M Deutschland GmbH | SIN05504P | INJECTION | 0.005 mg/ml | 2/26/1991 |
| UBISTESIN FORTE INJECTION | 3M Deutschland GmbH | SIN05505P | INJECTION | 0.01 mg/ml | 2/26/1991 |
| CITOCARTIN 100 INJECTION 1.7 ml/cartridge | SIN12648P | INJECTION | 10 mcg/ml | 3/7/2005 | |
| ECOCAIN INJECTION 2% | SIN12649P | INJECTION | 12.5 mcg/ml | 3/7/2005 | |
| SCANDONEST 2% SPECIAL INJECTION | SPECIALITES SEPTODONT | SIN07074P | INJECTION | 0.010mg/ml | 6/24/1992 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP | alveda pharmaceuticals inc | N/A | Liquid - Block/Infiltration | 0.01 MG / ML | 12/1/2008 |
| LIDOCAINE HYDROCHLORIDE 1.5% AND EPINEPHRINE 1:200000 INJECTION USP | hospira healthcare ulc | 02439433 | Solution - Block/Infiltration
,
Epidural | 0.005 MG / ML | N/A |
| ADAPTAGEN | bio active canada ltd. | 02233546 | Liquid - Oral | 12 X | 5/26/1998 |
| LIGNOSPAN STANDARD | 00375780 | Solution - Block/Infiltration | 18 MCG / 1.8 ML | 12/31/1976 | |
| LIDOCAINE 2% AND EPINEPHRINE 1:100,000 | carestream health canada company | 02270978 | Solution - Block/Infiltration | 0.01 MG / ML | 11/15/2005 |
| ANAPEN JUNIOR | Endo Operations Ltd. | 02306743 | Solution - Intramuscular | 0.15 MG / 0.3 ML | 11/23/2009 |
| ORABLOC 1:200,000 | 02361906 | Solution - Block/Infiltration | 0.009 MG / ML | 6/14/2012 | |
| NASAL SPRAY | botanical laboratories inc. | 02233407 | Liquid - Nasal | 6 X | 4/15/1998 |
| TAROCLICK EPINEPHRINE JUNIOR | 02480352 | Solution - Intramuscular | 0.15 MG / 0.3 ML | N/A | |
| TAROCLICK EPINEPHRINE | 02480344 | Solution - Intramuscular | 0.3 MG / 0.3 ML | N/A |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| Epistaxol solución cutánea | Medical S.A. | 42972 | SOLUCIÓN CUTÁNEA | Sin Receta | Commercialized |
| ADRENALINA LEVEL 1mg/ml SOLUCION INYECTABLE JERINGA PRECARGADA | Laboratorios Ern S.A. | 35403 | SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA | Medicamento Sujeto A Prescripción Médica | Commercialized |
| ANAPEN 0,50 MG/0,3 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA | 83253 | SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| ANAPEN 0,30 mg/0,3 ml SOLUCION INYECTABLE EN JERINGA PRECARGADA | 75409 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| ALTELLUS 150 MICROGRAMOS NIÑOS, SOLUCION INYECTABLE EN PLUMA PRECARGADA | 67263 | SOLUCIÓN INYECTABLE EN PLUMA PRECARGADA | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| ULTRACAIN CON ADRENALINA 40 MG/ML + 5 MICROGRAMOS/ML SOLUCION INYECTABLE | Laboratorios Normon S.A. | 55034 | SOLUCIÓN INYECTABLE EN CARTUCHO | Medicamento Sujeto A Prescripción Médica | Commercialized |
| ANAPEN 0,15 mg/0,3 ml SOLUCION INYECTABLE EN JERINGA PRECARGADA | 75408 | SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| ULTRACAIN CON ADRENALINA 40 MG/ML + 10 MICROGRAMOS/ML SOLUCION INYECTABLE | Laboratorios Normon S.A. | 55033 | SOLUCIÓN INYECTABLE EN CARTUCHO | Medicamento Sujeto A Prescripción Médica | Commercialized |
| LIDOCAINA/ADRENALINA NORMOGEN 20 MG/ML + 0,0125 MG/ML SOLUCION INYECTABLE EFG | Laboratorios Normon S.A. | 89517 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Commercialized |
| XYLONOR 2 % ESPECIAL | 51081 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.